Evaluating the De-Escalation of Surveillance for Patients Who Have Undergone Curative Treatment for Primary Breast Cancer
NCT07616258 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 560
Last updated 2026-06-01
Summary
Breast cancer is the most common cancer in women around the world. That means a lot of women are affected by it every year, and it's important that we always look for ways to improve their care, not just during treatment, but afterwards too. After treatment for early-stage breast cancer, patients usually come back to the hospital for regular check-ups for up to five years. These visits are based on old guidelines, and even though breast cancer treatment has improved a lot over the years, the follow-up schedule has stayed the same. This study is being done to see if we can safely reduce the number of hospital visits after treatment, while still keeping patients healthy and well looked after.
Right now, patients are asked to attend follow-up appointments at 6, 12, 18, 24, 36, 48 and 60 months (that's every 6 to 12 months for five years). These clinic visits often involve long waits and can cause stress or anxiety. At the same time, patients are also invited for a mammogram once a year. Recent research shows that most recurrences of breast cancer are found by patients themselves or during their annual mammograms, not necessarily at these clinic visits. That's why we're looking at whether we can safely reduce the number of hospital appointments, without affecting patient safety.
In this study, some patients will continue with the usual five-year clinic schedule. Others will only attend hospital clinics for the first two years (at 6, 12, 18 and 24 months), and after that, they will no longer need to come in for the extra follow-up visits, but they will still have their annual mammograms as normal.
Within this study all participants will complete a short questionnaire once a year. This will help us understand how the different follow-up plans affect quality of life, and how patients feel about their care. This research study is taking place to find out if fewer hospital check-ups, combined with continued mammogram screening, is just as safe and possibly better for patients' wellbeing.
Conditions
Interventions
- OTHER
-
De-Escalation of Management
Reduction in hospital based appointments to 2 years only and discharge to primary care for follow up post same.
- OTHER
-
Control
Standard of care
Sponsors & Collaborators
-
Royal College of Surgeons, Ireland
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-10-02
- Primary Completion
- 2027-12-30
- Completion
- 2028-12-30
Countries
- Ireland
Study Locations
More Related Trials
-
Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer
NCT03165006 ·Status: COMPLETED
-
Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy
NCT00897299 ·Status: COMPLETED
-
Recurrence Risk Evaluation by 21-gene Detection
NCT03841266 ·Status: COMPLETED
-
Evaluating Scaleup of an Adapted Breast Cancer Early Diagnosis Program in Rwanda
NCT05364138 ·Status: COMPLETED
-
Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer
NCT07617025 ·Status: RECRUITING
-
Interventions to Increase Screening by Breast Cancer Survivors and Their High Risk Female Relatives
NCT01612338 ·Status: COMPLETED ·Phase: NA
-
Patient Empowerment by Group Medical Consultations
NCT01329068 ·Status: UNKNOWN ·Phase: NA
-
Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer
NCT01282931 ·Status: COMPLETED
-
Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer
NCT05658172 ·Status: RECRUITING ·Phase: NA
-
Predictive Clinical and Biological Parameters in Breast Cancer
NCT01521676 ·Status: TERMINATED ·Phase: NA
-
Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer
NCT02530008 ·Status: ACTIVE_NOT_RECRUITING
-
LCCC1931:Post-treatment Intervention in Women With Breast Cancer (70y/o+)
NCT04292847 ·Status: COMPLETED
-
Study for the Knowledge of Risk Factors Associated With Breast Cancer in Women
NCT03918668 ·Status: COMPLETED
-
Cancer Prevention in Women With a BRCA Mutation
NCT02225015 ·Status: UNKNOWN ·Phase: PHASE1
-
Tumor Integrating Gut Microbiota in bREast Cancer
NCT07253168 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Factors Associated With Breast Cancer Risks and Outcomes
NCT07294703 ·Status: RECRUITING
-
Healthy Lifestyles and Quality of Life in Women With Breast Cancer
NCT04379908 ·Status: COMPLETED
-
Gene Expression Profiling to Help Define the Need for Neo-Adjuvant Chemotherapy in HR+, HER- Breast Cancer Patients
NCT05666258 ·Status: RECRUITING
-
Reproductive Health in Breast Cancer Survivor
NCT06756802 ·Status: ACTIVE_NOT_RECRUITING
-
Multiscale Omics for the Development of a Cohort Database and Study Platform in Breast Cancer Survivors
NCT04999826 ·Status: COMPLETED
-
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
NCT04797299 ·Status: RECRUITING
-
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
NCT00006421 ·Status: COMPLETED
-
Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation
NCT05763472 ·Status: UNKNOWN
-
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
NCT00040222 ·Status: COMPLETED
-
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
NCT06274541 ·Status: COMPLETED